临床-超声预测模型评估DCIS升期风险的探索性研究
本研究回顾性纳入2019年2月至2024年12月于国家癌症中心经穿刺活检确诊为导管原位癌并接受手术的224例患者,其中128例最终病理存在微浸润或浸润性癌。基于超声及临床特征构建多因素Logistic回归模型,用于识别病理升期低风险患者,以辅助DCIS主动监测试验的入组筛选。
要点
- 超声显示非平行生长、可触及肿块、Adler II-III级血流及腋窝淋巴结异常时,DCIS病理升期风险显著升高。
- 超声测量病灶大小是升期的独立预测因素,报告中应记录具体径线。
- 该模型AUC为0.784,可作为DCIS主动监测入组筛选的探索性参考。
核心结论
- 基于常规临床与超声特征构建的预测模型对穿刺确诊DCIS的病理升期风险具有可接受的区分能力,AUC为0.784。
研究设计与样本
- 回顾性研究,纳入2019年2月至2024年12月在国家癌症中心经粗针穿刺活检确诊DCIS并接受手术的224例患者。
- 收集临床资料与超声特征,并选取部分乳腺X线及MRI变量进行探索性分析。
- 采用多因素Logistic回归构建预测模型。
关键影像表现/征象
- 超声声像图表现为非平行生长方向时,升期风险显著增高。
- 超声检出血流信号Adler分级II-III级与升期风险相关。
- 超声发现腋窝淋巴结异常是升期的独立预测因素。
- 临床可触及肿块是升期的独立预测因素。
诊断标准与关键数值
- 多因素分析显示:超声测量大小OR为2.363,p=0.02;可触及肿块OR为2.675,p=0.02。
- 超声非平行生长方向OR为4.449,p<0.001;血流Adler II-III级OR为2.357,p=0.014。
- 超声检出腋窝淋巴结异常OR为5.262,p=0.002。
- 模型由上述五个变量构成,AUC为0.784(95%CI:0.723-0.845),总体准确率为72.3%。
临床应用与阅片要点
- 对穿刺确诊DCIS患者行超声检查时,应重点评估病灶生长方向、血流分级及腋窝淋巴结状态。
- 报告中应明确记录病灶最大径及是否可触及,以辅助升期风险评估。
局限性
- 本研究为探索性研究,模型性能需在前瞻性队列中验证。
- 研究为单中心回顾性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This exploratory study aimed to develop a practical prediction model using clinical and sonographic features to identify patients with biopsy-proven ductal carcinoma in situ (DCIS) who are at low risk of pathological upstaging, with the goal of informing patient selection for DCIS active surveillance trial enrollment.
METHODS: We retrospectively analyzed patients with DCIS diagnosed by core needle biopsy who underwent surgery at the National Cancer Center between February 2019 and December 2024. Clinical data and sonographic features were collected, along with selected mammographic and MRI variables for exploratory analysis. A predictive model was constructed by using multivariable logistic regression.
RESULTS: We identified 224 patients diagnosed with DCIS through biopsy, including 96 pure DCIS cases (42.9%) and 128 DCIS cases with microinvasion (28.1%) or invasive carcinoma (29.0%) on final pathology. Multivariate analysis identified sonographic size (odds ratio [OR] 2.363, p = 0.02), palpable mass (OR 2.675, p = 0.02), non-parallel growth orientation on ultrasound (OR 4.449, p < 0.001), vascularity (Adler grade II-III) (OR 2.357, p = 0.014) and sonographically detected axillary lymphadenopathy (OR 5.262, p = 0.002) as independent predictors of upstaging. The predictive model constructed from these five variables achieved an area under the curve of 0.784 (95% confidence interval: 0.723-0.845) with overall accuracy of 72.3%.
CONCLUSION: The proposed model based on routine clinical and sonographic features provided reasonable discrimination for upstaging risk in patients with biopsy-proven DCIS. It may serve as a useful exploratory reference for refining patient selection in active surveillance trial design.
引用
- Feng, He, Wang, et al. A Clinical-Ultrasound Predictive Model for Upstaging Risk in DCIS: An Exploratory Tool for Active Surveillance Trial Enrollment. Ultrasound Med Biol. 2026. PMID: 42629304. doi:10.1016/j.ultrasmedbio.2026.07.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。